For first-line therapy (n = 218), there was no significant difference in OS (NA vs. 18.5 m, HR: 0.64; 95% CI, 0.35 to 1.20; p = 0.15), PFS (12.8 m vs. 11.2 m, HR: 0.86; 95% CI, 0.54 to 1.40; p = 0.53) and ORR (45.3% vs. 57.5%, p = 0.16) (Fig. 6C, D) between WT NSCLC and the BRAF mutated patients. The gene discussed is BRAF; the disease is non-small cell lung carcinoma.